Register Login
Register to leave comments
  • News bot Oct. 30, 2025, 10:34 a.m.

    📋 Agios Pharmaceuticals, Inc. (AGIO) - Financial Results

    Filing Date: 2025-10-30

    Accepted: 2025-10-30 06:32:30

    Event Type: Financial Results

    Event Details:

    Agios Pharmaceuticals Inc (AGIO) Reports Q4 2025 Financial Results Agios Pharmaceuticals Inc (AGIO) announced its financial results for the period ending Q4 2025. Key Financial Highlights:
    • Revenue: 1679
    • Net Income: $947
    • EPS: Not disclosed
    • Cash and equivalents: 1257201
      • world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial
      • stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.Cautionary Note Regarding Forward
      • Looking Statements This press release contains forward
        • expected by year-end, potentially supporting a U.S. commercial launch in 2026
        • expected by early 2026
        • expected in early 2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2025 2024 Change ($) Change (%)
    Cash Equivalents Marketable Securities 1.26M 1.26M $0.00 +0.00%
    Operating Expenses Selling General Administrative 38.54K 128.67K $-90.13K -70.05%
    Operating Expenses Loss From Operations -102.81K -350.55K $247.74K +70.67%
    Other Income Net 1.65K 1.84K $-192.00 -10.42%
    Cash and Marketable Securities 1.26M 1.53M $-274.83K -17.94%
    Revenue 8.96K 8.96K $0.00 +0.00%
    Selling, General & Administrative 38.54K 128.67K $-90.13K -70.05%
    Loss from Operations -102.81K -350.55K $247.74K +70.67%
    Interest Income 13.06K 43.97K $-30.91K -70.30%
    Other Income, Net 1.65K 1.84K $-192.00 -10.42%
    Net Loss 1.00M -304.74K $1.31M +428.49%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Agios Pharmaceuticals Inc
    • CIK: 0001439222
    • Ticker Symbol: AGIO
    • Period End Date: 2025-10-30
    • Document Type: 8-K

Search

News categories